iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference
iOnctura, a pioneering clinical-stage biopharmaceutical company, is making waves in the oncology sphere with its innovative approach to treating neglected and hard-to-treat cancers. On January 15, 2026, the company’s CEO, Catherine Pickering, is set to take center stage at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco, California. This prominent event is renowned as the world’s largest and most influential healthcare investment conference and is an invite-only gathering that brings together key players from the pharmaceutical and biotechnology sectors.
Dr. Pickering's presentation will underscore iOnctura's clinical advancements, particularly focusing on its flagship project, roginolisib. This groundbreaking small molecule is recognized as the first allosteric modulator of PI3Kδ, a significant pathway in various cancers. The significance of Dr. Pickering's appearance at this esteemed conference highlights the growing recognition and visibility of iOnctura within the global oncology ecosystem, and serves as a platform for fostering innovation and capital formation in the field.
"Being invited to present at this year’s J.P. Morgan Healthcare Conference is an honor for us," stated Pickering. "This acknowledgment reflects the increasing interest in our science-driven approach and the meaningful clinical progress we have achieved with roginolisib. We eagerly anticipate the opportunity to showcase our advancements and engage with partners committed to transforming cancer care."
The company's lead product, roginolisib, presents a novel approach as a non-ATP competitive, allosteric modulator of PI3Kδ with a unique chemical structure. This innovative mechanism of action allows for precise inhibition of PI3Kδ, potentially providing clinical benefits without the adverse side effects typically associated with earlier generations of inhibitors. The clinical potential of roginolisib has garnered positive signals from ongoing Phase I studies in both solid tumors and hematological malignancies, showcasing the drug's ability to double overall survival rates in rare conditions like uveal melanoma.
iOnctura has an ambitious clinical program established to validate roginolisib across multiple trials including the Phase II OCULE-01 study targeting uveal melanoma, which commenced in March 2025, and the PULMO-01 study focusing on non-small cell lung cancer that kicked off in May 2025. Moreover, the HEMA-MED Phase I/II study investigating myelofibrosis began in November 2025, further exemplifying the company’s commitment to addressing significant unmet needs in cancer treatment.
iOnctura, headquartered in Amsterdam with additional offices in Geneva and Cambridge, Massachusetts, is backed by several specialist institutional investors, demonstrating considerable confidence in the company's strategic vision and pipeline. The firm’s mission is clear: to deliver first-in-class small molecules that extend lives and enhance health spans, ultimately transforming the outlook for patients battling cancer.
As iOnctura gears up for the J.P. Morgan conference, it not only highlights its own progress but serves as a beacon of hope in the ongoing battle against cancer, exhibiting how innovation in biotechnology can pave the way for new treatments and a better quality of life for patients worldwide.
Dr. Pickering's presentation will underscore iOnctura's clinical advancements, particularly focusing on its flagship project, roginolisib. This groundbreaking small molecule is recognized as the first allosteric modulator of PI3Kδ, a significant pathway in various cancers. The significance of Dr. Pickering's appearance at this esteemed conference highlights the growing recognition and visibility of iOnctura within the global oncology ecosystem, and serves as a platform for fostering innovation and capital formation in the field.
"Being invited to present at this year’s J.P. Morgan Healthcare Conference is an honor for us," stated Pickering. "This acknowledgment reflects the increasing interest in our science-driven approach and the meaningful clinical progress we have achieved with roginolisib. We eagerly anticipate the opportunity to showcase our advancements and engage with partners committed to transforming cancer care."
The company's lead product, roginolisib, presents a novel approach as a non-ATP competitive, allosteric modulator of PI3Kδ with a unique chemical structure. This innovative mechanism of action allows for precise inhibition of PI3Kδ, potentially providing clinical benefits without the adverse side effects typically associated with earlier generations of inhibitors. The clinical potential of roginolisib has garnered positive signals from ongoing Phase I studies in both solid tumors and hematological malignancies, showcasing the drug's ability to double overall survival rates in rare conditions like uveal melanoma.
iOnctura has an ambitious clinical program established to validate roginolisib across multiple trials including the Phase II OCULE-01 study targeting uveal melanoma, which commenced in March 2025, and the PULMO-01 study focusing on non-small cell lung cancer that kicked off in May 2025. Moreover, the HEMA-MED Phase I/II study investigating myelofibrosis began in November 2025, further exemplifying the company’s commitment to addressing significant unmet needs in cancer treatment.
iOnctura, headquartered in Amsterdam with additional offices in Geneva and Cambridge, Massachusetts, is backed by several specialist institutional investors, demonstrating considerable confidence in the company's strategic vision and pipeline. The firm’s mission is clear: to deliver first-in-class small molecules that extend lives and enhance health spans, ultimately transforming the outlook for patients battling cancer.
As iOnctura gears up for the J.P. Morgan conference, it not only highlights its own progress but serves as a beacon of hope in the ongoing battle against cancer, exhibiting how innovation in biotechnology can pave the way for new treatments and a better quality of life for patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.